Red Light Holland and PharmAla notch psilocybin extraction

Red Light Holland (CSE:TRIP) reveals it has successfully completed the first phase of psilocybin extraction to PharmAla Biotech (CSE:MDMA).

Optimi Health to advance psychedelic clinical trials

Optimi Health (CSE:OPTI) signs letter of intent with ATMA Journey Centers to advance its psilocybin extract into a psilocybin clinical trial.

Optimi Health certified for increased MDMA capsule dosages

Optimi Health (CSE:OPTI) confirms its formulated MDMA meets Good Manufacturing Practice specifications after third-party laboratory testing.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Red Light Holland and Costco Canada partner on mushroom kits

Red Light Holland (CSE:TRIP) partners with Costco Canada to launch Mega Block, a 2-kilogram home-grow mushroom kit, in late May.

CCrest Labs receives Red Light Holland’s largest psilocybin order

Red Light Holland's (CSE:TRIP) largest shipment to date of 5 kilograms of psilocybin truffles has been received by CCrest Labs in Montreal.

Red Light Holland reports record psilocybin shipment

Psychedelics stock Red Light Holland (CSE:TRIP) exports 5 kilograms of natural psilocybin truffles to CCrest Laboratories in Montreal.

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.

Red Light Holland and PharmAla to collaborate on medical psilocybin

Red Light Holland (CSE:TRIP) has entered into a collaboration with PharmAla Biotech Holdings (CSE:MDMA) for medical psilocybin.

Numinus Wellness offers turnkey exposure to psychedelic medicine

Stock investors searching for holistic exposure to psychedelic medicine should add Numinus Wellness to their due diligence lists.
PharmAla Biotech - PharmAla's LaNeo MDMA capsules.

PharmAla approved to sell MDMA and psilocybin in Canada

Health Canada has cleared PharmAla Biotech (CSE:MDMA) to sell MDMA and psilocybin to anyone legally permitted to hold them.

Clearmind posts results from weight loss pre-clinical trial

Clearmind Medicine (CSE:CMND) has revealed positive results from its weight loss pre-clinical trial in animal subjects.

Optimi Health completes psilocybin extract validation

Optimi Health (CSE:OPTI) has reached a significant milestone, the successful harvest of eight new natural psilocybin genetics.

First trial to assess real-world efficacy of MDMA in treating PTSD

PharmAla Biotech (CSE:MDMA) will start an observational trial on patients treated with 3,4 Methylenedioxymethamphetamine (MDMA).